Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients

Patricia G. Hoogeveen, Maaike de Bie, Rianne Noordijk, Edwin Sonneveld, Anneke Koning-Goedheer, H. Berna Beverloo & Vincent H.J. van de der Velden

To cite this article: Patricia G. Hoogeveen, Maaike de Bie, Rianne Noordijk, Edwin Sonneveld, Anneke Koning-Goedheer, H. Berna Beverloo & Vincent H.J. van de der Velden (2018) Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients, Leukemia & Lymphoma, 59:6, 1508-1510, DOI: 10.1080/10428194.2017.1382699

To link to this article: https://doi.org/10.1080/10428194.2017.1382699

© 2017 Erasmus MC. Published by Informa UK Limited, trading as Taylor & Francis Group

Published online: 28 Sep 2017.

Article views: 313

View supplementary material
Submit your article to this journal
View Crossmark data
LETTER TO THE EDITOR

Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients

Patricia G. Hoogeveena, Maaike de Biea, Rianne Noordijka, Edwin Sonneveldb, Anneke Koning-Goedheerb, H. Berna Beverlooc and Vincent H.J. van de der Veldena

aDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; bDutch Childhood Oncology Group, The Hague, The Netherlands; cDepartment of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

ARTICLE HISTORY Received 28 August 2017; revised 12 September 2017; accepted 18 September 2017

Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and many adult ALL patients [1]. MRD diagnostics has proven to be the strongest prognostic factor, allowing for risk group assignment into different treatment arms, resulting in significant treatment reduction or mild or strong intensification. Within the Dutch Childhood Oncology Group (DCOG) ALL10 protocol, MRD-based low-risk patients received significant treatment reduction, resulting in an excellent outcome with very few side effects [2].

Given the significant treatment reduction of MRD-negative patients within the DCOG-ALL10 protocol, the strict criteria of the MRD-based low-risk group of the original I-BFM-SG study [3] have been retained to define MRD negativity, using at least two different types of sensitive immunoglobulin (IG)-T-cell receptor (TR) polymerase chain reaction (PCR) targets, thereby avoiding or reducing oligoclonality problems and related false negativity [3-5].

Table 1. Results of STR analysis and possible explanation by cytogenetic findings.

<table>
<thead>
<tr>
<th>Patient</th>
<th>STR analysis</th>
<th>Cytogenetics</th>
<th>Difference in STR explained?</th>
</tr>
</thead>
<tbody>
<tr>
<td>LR-02</td>
<td>vWA (12p) shift in Dx</td>
<td>55, XY, +X, dup(1)(q21q42), +4, +6, +10, +14, +17, +18, +21, +21[16]/46,XY[3]</td>
<td>No</td>
</tr>
<tr>
<td>LR-05</td>
<td>D165539 (16q) missing in Dx</td>
<td>47, XX, +X, add(2)(p11), add(3)(q25), −13, −16, −17, −17, −19, −20, −21c, +Smar[7]/48, idem, +8[9]/47, XX, +21c[4]</td>
<td>Yes</td>
</tr>
<tr>
<td>LR-11</td>
<td>D75820 (7q) extra peak in Dx</td>
<td>46, XY, t(6;7)(q23;q34)[6]/46,XY[5]</td>
<td>Yes</td>
</tr>
<tr>
<td>IR-05</td>
<td>D13S317 (13q) missing in Dx</td>
<td>45, XY, add(7)(q36), add(12)(p13), −13/12[14],46,XY[6]</td>
<td>Yes</td>
</tr>
<tr>
<td>IR-16</td>
<td>CSF1PO (5q) missing in Dx; vWA (12p) missing in Dx</td>
<td>46, XY, del(2)(q22q31), add(12)(p172), del(12)(p117)[7]/44,XY, del(2)(q22q31), −5, −9, add(12)(p112)</td>
<td>Yes</td>
</tr>
<tr>
<td>LR-30</td>
<td>vWA (12p) missing in Dx</td>
<td>46, XX, del(2)(q32q34)[11]/46,XX[2]</td>
<td>No</td>
</tr>
<tr>
<td>IR-16</td>
<td>THO (11p) missing in Dx</td>
<td>56 − 59, XX, +X[12], +X[3], der(2;22)(q10;q10), +4, −4[8], +6, −8[7], −10, +14[11], +16[3], +17[5], +add(17)(q25)[9], +18, +21, +22, +1 ~ 4mar[13]/46,XX[6]</td>
<td>No</td>
</tr>
<tr>
<td>IR-21</td>
<td>D75820 (7q), CSF1PO (5q), THO1 (11p), D2S1338 (2q), D19S433 (19q), vWA (12p), TPOX (2p), DSS5818 (5q), FGA (4g) all missing in Dx</td>
<td>28 &lt; n &gt; X+Y, +10, +14, +18, +21/11,46,XY[3]</td>
<td>Yes</td>
</tr>
<tr>
<td>IR-30</td>
<td>vWA (12p) missing in Dx</td>
<td>45, XX, del(1)(p11), der(9)(t;9:14)(p173q171), der(13;22)(q10;q10), −14, +21c[5]/45, idem, +1, −del(1)[p11], add(12)[p17], −20, +mar[5]/44, idem, +add(1)[p172], −del(1)[p11], add(7)[p21], −12[11]/47, XX, +21c[3]</td>
<td>Yes</td>
</tr>
</tbody>
</table>

FISH: t(12;21) present with loss of normal 12p13/ETV6

CONTACT Vincent H. J. van der Velden v.h.vandervelden@erasmusmc.nl Department of Immunology, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
© 2017 Erasmus MC. Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
However, false negativity may also be caused by mixing up patient samples [6,7], resulting in under-treatment of the corresponding patient and increased relapse risk. We used short tandem repeat (STR) analysis to evaluate whether sample mix-up occurred in low-risk (LR) ALL patients treated within the DCOG-ALL10 protocol.

The DNA samples from 30 LR patients used for MRD diagnostics at diagnosis, day 33 and day 78 were evaluated by STR analysis using the PowerPlex® 16 system (Promega, Leiden, the Netherlands). This kit evaluates 15 tetranucleotide repeat loci on different chromosomal positions. In addition, diagnostic and day 33 samples from 20 intermediate risk (IR; MRD positive at day 33, therefore confirmed not to be mixed up) were used for comparison.

In five out of 30 LR patients (16.7%), differences were observed between the diagnostic sample and the follow-up sample(s) in one or more evaluated STR (Table 1 and Figure 1(A)). Of note, for the LR patients, the STR patterns in the two follow-up samples were always identical, suggesting that sample mix up was unlikely. This was supported by the finding that also in 5 out of 20 (25%) IR

![Figure 1](image.png)

**Figure 1.** STR results of patient IR-16. (A) Diagnostic sample (top row) versus follow-up (bottom row). In the diagnostic sample, an STR for THO (11p) seems missing as compared to the follow-up sample. (B) Nonsorted cells (top row) versus sorted ALL cells (middle row) and sorted normal cells (bottom row) of the same patient clearly show specific loss of a STR in the leukemic cells.
patients differences in one or more STRs were observed (Table 1). Therefore, instead of a results of sample mix up, the differences in STR pattern more likely are related to differences between leukemic cells (predominant in the diagnostic sample) and normal cells (predominant in the follow-up samples). We therefore evaluated these 10 cases with STR differences with respect to their cytogenetic findings. Indeed, in seven out of 10 cases, the difference in STR pattern could be explained by the chromosomal abnormalities in the leukemic cells (Table 1). Three cases (LR-02; LR-30 and IR-16), however, could not be explained by the cytogenetic data. For these cases, both the leukemic cells and normal cells from the (viably frozen) diagnostic sample were separated by FACS-sorting and STR was performed on the sorted cell populations. In all three cases, the STR pattern in the sorted normal cells from diagnosis was similar to the STR pattern in the follow-up samples, whereas the STR pattern of the sorted leukemic cells was different (and identical to the STR pattern of the nonsorted diagnostic sample) (Figure 1(B)). These data therefore further confirm that the different STR pattern between diagnosis and follow-up is not related to sample mix up but indeed reflects the genetic abnormalities present in the leukemic cells. MLPA analysis (SALSA MLPA P335 ALL-IKZF1 probe mix; MRC-Holland, Amsterdam, the Netherlands) was performed in these three patients. In patient LR-30, a deletion of the ETV6 gene on 12p13 was observed by FISH, whereas by STR analysis one allele for VWF on 12p12 was lost, suggesting a deletion both comprising 12p12 and 12p13. In the two other patients, MLPA analysis did not explain the STR data. It may be expected that also in patient IR-16 the missing THO STR is due to a small chromosomal deletion not detected by routine cytogenetics. We have no explanation for the shift in the VWF STR in patient LR-02, but genetic changes in the leukemic cells apparently occurred in this locus.

Our data show that sample mix up had not occurred in the LR patients evaluated in this study. In addition, our data show that the interpretation of STR data from samples obtained from leukemic patients, comparatively to patients with other malignancies [8–10], is not always straight-forward but can be hampered by changes in the STR pattern caused by genetic changes in the malignant cells. Results of subsequent STR analyses should therefore be interpreted with care.

**Potential conflict of interest:** Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1382699.

**References**


